Spyre Therapeutics Reports Q3 2026 Net Loss of $96.1 Million, Advances IBD and HS Programs

What happened

Spyre Therapeutics reported a third-quarter 2026 net loss of $96.1 million, compared with a net loss of $11.2 million a year earlier. The company ended September with $1.07 billion in cash, cash equivalents and marketable securities, and reported positive induction data for SPY003.

Confirmed

Global impact / market context

The much larger loss came as research and development spending rose to $89.2 million, which means the company is spending heavily to push its inflammatory bowel disease and hidradenitis suppurativa programs forward. Its large cash balance gives it room to keep funding those trials.

Analyst inference

Spyre is a clinical-stage biotechnology company, meaning it has no approved products and relies on investor cash to fund trials. Its $1.07 billion cash position and $1.47 billion pro forma cash after October financing suggest the higher spending is covered for now.

Analyst inference

What to watch

1. Research and development expenses were $89.2 million for the quarter, up from $45.2 million a year earlier. Net cash used in third-quarter operating activities was $77.5 million. Confirmed
2. Investors may want to see whether Spyre's SPY003 induction results in the Phase 2 SKYLINE trial hold up in later stages, since the company called them proof-of-concept. Proposed
3. Watch whether Spyre's spending keeps rising as its bowel disease and skin disease programs advance, because faster cash use would shorten how long its $1.47 billion pro forma cash lasts. Analyst inference

Evidence

• Original source link unavailable